Transcript
Maybelline Representative (0:00)
Ever wonder what your lashes are destined for? The cards have spoken. Maybelline New York Mascara does it all. Whether you crave fully fan lashes with lash Sensational big bold volume from the colossal a dramatic lift with falsies lash lift or natural looking volume from great lash. Your perfect lash future awaits. Manifest your best mascara today. Shop Maybelline New York and discover your lash destiny. Shop now at Walmart.
Fin Representative (0:25)
Hey, you know what would make your customer service help desk way better? Dumping it and then switching to intercom. But you're not quite ready to make that change. We get it. That's why Fin, the world's leading AI customer service agent is now available on every help desk. Fin can instantly resolve up to 80% of your tickets, which makes your customers happier and gets you off the customer service rep hiring treadmill Fin by Intercon the leading customer service AI agent now available on every help desk.
Paige Desorba (0:54)
This is Paige Desorba from Giggly Squad. Opill is a game changer for sexual reproductive health. They're the first over the counter daily birth control pill available in the U.S. finally, the days of needing a prescription to get birth control are over. Opill is FDA approved, no prescription needed, full prescription strength, estrogen free and available online and at most major retailers. So when there's no prescription, no appointment, there's no hassle, no more waiting at the doctor's office to get a prescription. Opill will be easily accessed over the counter, in store or online and will be ready for when you need it. Opill is available online and at most major retailers. Use code giggly for 25% off your first month of opill@opill.com from executive producer Isaac Saul.
Isaac Saul (1:49)
This is Tangle. Good morning, good afternoon and good evening and welcome to the Tangle podcast, a place you get views from across the political spectrum, some independent thinking and a little bit of my take. I'm your host, Isaac Soule and on today's episode we're going to be talking about the latest in the India Pakistan conflict. If you've been paying attention to the news, you probably see some headlines about what's going on. I know many of our listeners are not familiar with this issue. Personally, I, you know, I have some knowledge on it but have also done a lot of learning over the last few years. So we're going to start by trying to just give you some historical context, break down exactly what happened, explain the news a little bit and then we're going to share some arguments from the left and right. Right. And then I'm going to share my Take. Before we jump in, though, I do want to give you a quick heads up that tomorrow we're going to be debuting something that I'm really excited about. I don't know if we're going to make this a recurring series, but I think there's a chance we do. And it's this idea of going back to some news stories that were at some time dominant in the headlines that felt like these existential major issues that were gonna be with the country for a long time and then just sort of disappeared, faded into the background, kind of got memory hold by people. And we're gonna start tomorrow with a newsletter and a podcast on what happened to the baby formula shortage. Do you remember that? I kind of forgot about it, but for a large period of a month, I think we were being told that there was gonna be this massive baby formula shortage that we weren't really sure how to get out of it. And then the story kind of just dissipated, just floated off into the ether and everyone sort of forgot about it and moved on. And we want to revisit stories like that. And we're thinking about making this a recurring series, but we're curious for your thoughts. So we're going to start tomorrow with a revisitation of the baby formula shortage. And if you like the podcast, feel free to let us know because it's something we're thinking about doing as a sort of thematic, recurring. All right, with that, I'm going to pass it over to John for today's main topic and I'll be back for my take.
